En este vídeo vamos a hablar de uno de los mayores malentendidos de los últimos 50 o 60 años: Que el colesterol LDL alto no te provoca infartos y que el colesterol LDL bajo no te protege de ellos.
Hoy en día sabemos que el mejor marcador de riesgo de aterosclerosis no es el colesterol, sino el número de partículas LDL que tenemos circulando por la sangre, lo cual se mide por la proteína APO B.
Para entender del todo este problema, vamos a verlo desde distintos ángulos.
Tenemos que saber cuál es el mecanismo por el que se produce la aterosclerosis, cual es la ciencia que lo respalda y por qué estábamos equivocados.
PARTES DEL VÍDEO:
0:00 - Introducción
1:49 - ¿Cómo se produce la aterosclerosis?
5:20 - ¿Qué es el APO B? LDL-C vs LDL-C
7:10 - ¿Tener el colesterol alto es malo?
9:30 - ¿Por qué estábamos equivocados?
11:05 - Discordancia y Síndrome Metabólico
13:05 - Las analíticas estándar nos pueden engañar
BIBLIOGRAFÍA:
1 Atherosclerotic Cardiovascular Disease Beginning in Childhood
2 Role of hypertension in atherosclerosis and cardiovascular disease
3 Endothelial Dysfunction and Coronary Artery Disease: Assessment, Prognosis and Treatment
4 Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis Update and Therapeutic Implications
5 - LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA)
LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA)
6 Small, Dense Low-Density Lipoprotein Particles as a Predictor of the Risk of Ischemic Heart Disease in Men
7 Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients
8 LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management
9 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations
10 Apolipoprotein B but not LDL Cholesterol Is Associated With Coronary Artery Calcification in Type 2 Diabetic Whites
11 American Association of Clinical Endocrinologists/American College of Endocrinology Management of Dyslipidemia and Prevention of Cardiovascular Disease Clinical Practice Guidelines
12 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
13 Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study
Discordance of Low Density Lipoprotein and High Density Lipoprotein Cholesterol Particle vs Cholesterol Concentration for the Prediction of Cardiovascular Disease in Patients with Metabolic Syndrome and Diabetes Mellitus (from the Multi-Ethnic Study of Atherosclerosis [MESA])
14 Evaluation of Low-Density Lipoprotein Particle Number Distribution in Patients With Type 2 Diabetes Mellitus With Low-Density Lipoprotein Cholesterol 50 mg/dl and Non-High-Density Lipoprotein Cholesterol 80 mg/dl
Hoy en día sabemos que el mejor marcador de riesgo de aterosclerosis no es el colesterol, sino el número de partículas LDL que tenemos circulando por la sangre, lo cual se mide por la proteína APO B.
Para entender del todo este problema, vamos a verlo desde distintos ángulos.
Tenemos que saber cuál es el mecanismo por el que se produce la aterosclerosis, cual es la ciencia que lo respalda y por qué estábamos equivocados.
PARTES DEL VÍDEO:
0:00 - Introducción
1:49 - ¿Cómo se produce la aterosclerosis?
5:20 - ¿Qué es el APO B? LDL-C vs LDL-C
7:10 - ¿Tener el colesterol alto es malo?
9:30 - ¿Por qué estábamos equivocados?
11:05 - Discordancia y Síndrome Metabólico
13:05 - Las analíticas estándar nos pueden engañar
BIBLIOGRAFÍA:
1 Atherosclerotic Cardiovascular Disease Beginning in Childhood
2 Role of hypertension in atherosclerosis and cardiovascular disease
3 Endothelial Dysfunction and Coronary Artery Disease: Assessment, Prognosis and Treatment
4 Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis Update and Therapeutic Implications
5 - LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA)
LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA)
6 Small, Dense Low-Density Lipoprotein Particles as a Predictor of the Risk of Ischemic Heart Disease in Men
7 Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients
8 LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management
9 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations
10 Apolipoprotein B but not LDL Cholesterol Is Associated With Coronary Artery Calcification in Type 2 Diabetic Whites
11 American Association of Clinical Endocrinologists/American College of Endocrinology Management of Dyslipidemia and Prevention of Cardiovascular Disease Clinical Practice Guidelines
12 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
13 Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study
Discordance of Low Density Lipoprotein and High Density Lipoprotein Cholesterol Particle vs Cholesterol Concentration for the Prediction of Cardiovascular Disease in Patients with Metabolic Syndrome and Diabetes Mellitus (from the Multi-Ethnic Study of Atherosclerosis [MESA])
14 Evaluation of Low-Density Lipoprotein Particle Number Distribution in Patients With Type 2 Diabetes Mellitus With Low-Density Lipoprotein Cholesterol 50 mg/dl and Non-High-Density Lipoprotein Cholesterol 80 mg/dl
- Category
- Metabolism

Be the first to comment